Company profile

Hyperfine Research, Inc

Medical Imaging & Radiology

Company profile

About Hyperfine Research, Inc

Hyperfine, Inc. (Nasdaq: HYPR) is a groundbreaking health technology company that has redefined brain imaging with the Swoop system—the first FDA-cleared, portable, ultra-low-field magnetic resonance brain imaging system capable of providing imaging at multiple points of care within healthcare facilities. Founded in 2014 by serial entrepreneur Jonathan Rothberg, PhD, Hyperfine's mission is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging and data solutions. The Swoop system is an AI-powered portable brain MRI that uses a magnet with a fraction of the field strength (0.064T) used in conventional MRI. This breakthrough enables the device to be brought directly to the point of care and used safely in almost any care setting without the need for dedicated staff or infrastructure. The system simply plugs into a standard electrical outlet and is ready to use in minutes, with an intuitive interface that any trained healthcare professional can operate. Powered by Optive AI software, the Swoop system brings advanced, AI-driven image reconstruction to ultra-low-field portable MRI, reducing noise and blur with deep learning to enhance image clarity and consistency. The system provides diagnostic-quality imaging across multiple sequences including T1, T2, FLAIR, and DWI in axial, coronal, and sagittal planes. Its open design and quieter operation enhance patient comfort and reduce anxiety, while eliminating exposure to ionizing radiation. Hyperfine serves diverse healthcare settings including hospital ICUs and emergency departments, neurology clinics, pediatric facilities, and underserved global markets. The company partners with organizations like the Gates Foundation, Raising Malawi, and the Hydrocephalus Association to expand access to neuroimaging in low- and medium-income countries. Hyperfine went public in December 2021, with Class A common stock trading on Nasdaq under the symbol HYPR.

Company description Hyperfine Research, Inc official website

Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Hyperfine Research, Inc?

Claim this profile to manage Company information and connect with the Health AI Central audience.

Claim this listing

01 · Operating footprint

Where the Company operates

Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.

Clinical focus

  • Birth asphyxia
  • Encephalitis
  • General brain imaging
  • Hydrocephalus
  • Malnutrition-related neurological damage
  • Meningitis
  • Sepsis
  • Stroke

Who it serves

  • Emergency Departments
  • Health Systems
  • Hospitals
  • ICUs
  • Neurology Clinics
  • Pediatric Facilities
  • Research Institutions

Deployment & integration

Embedded · On Premise deployment with recorded integration context.

Geographic context

MarketsAsia · Europe · Global · Malawi · Sub-Saharan Africa · United States
Company sourceOfficial website

Company milestones

Platform expansion

IPO in December 2021 on Nasdaq. Deployment of Swoop systems across multiple research and clinical study sites globally. Launch of Optive AI software for enhanced image reconstruction.

Partnerships

Recorded partners

  • Gates Foundation
  • Hydrocephalus Association
  • Mercy James Centre
  • Raising Malawi

02 · Flagship portfolio

Products, workflows, and platform capabilities

Selected source-backed Company products and the available commercial context.

Optive AI

AI-driven image reconstruction software for ultra-low-field portable MRI

Software · EmbeddedCompany source

Swoop Portable MR Imaging System

AI-powered portable brain MRI using ultra-low-field (0.064T) technology for point-of-care imaging

Device · On PremiseCompany source

03 · Research intelligence

Research Intelligence evidence

Publications, preprints, clinical validation, and regulatory records in Evidence Position order.

Evidence position

Publications, clinical validation, and regulatory records connected to this Company appear here.

04 · Company-reported outcomes

Outcomes and case studies

Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.

Faster diagnosis

Enables timely informed clinical decisions at point of care

Enhanced throughput

More effective, scalable stroke programs

Improved accessibility

Imaging for patients who cannot undergo traditional MRI

Mercy James Centre

Providing pediatric brain imaging in Malawi's first and only pediatric surgery and intensive care hospital, supporting critical care for infants and children

05 · Leadership

Leadership team

Leadership profiles and professional links from the current Company record.

Brett Hale

Brett Hale

Chief Administrative Officer and Chief Financial Officer

LinkedIn

Tom Teisseyre

Chief Operating Officer

Rob Fasciano

Chief Regulatory and Quality Officer

LinkedIn

Rafael Donnay

Senior Vice President of Hospital Business

LinkedIn

Chi Nguyen

Senior Vice President of Office and Community Business

Todd Finch

Vice President of US Sales

06 · Company updates

Updates from Hyperfine Research, Inc

Recent articles published on Hyperfine Research, Inc's official website.

07 · HAIC coverage

Coverage and analysis

Health AI Central reporting that mentions this Company.

No HAIC coverage is currently linked to this Company.

08 · Official presence

Company sources and channels

Curated official destinations from the active Company record.

09 · Market pathway

Additional Companies in this Market

Other active Companies in the same market, selected alphabetically from the HAIC directory.

Market context

Medical Imaging & Radiology

Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.

Explore the full market directory or compare this Company with additional active profiles.

View all Companies in this market

10 · Pro research

Coming soon

Expanded Company research is in development.

Health AI Central Pro · Coming Soon

Deeper Company research is coming soon.

Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.

ResearchEvidence analysis

Linked research, clinical, and regulatory source pathways.

CompanyTechnical context

Expanded product, deployment, integration, and partnership research.

MethodSource & review record

Record-level provenance and review context.

Coming Soon